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Alzheimer’s disease (AD) is a neurode-
generative disorder with insidious onset 
and progressive course, which prevalence 
increases with the age. It is characterized by 
neuronal degeneration and death, related to 
the deposition in the brain of the amyloid 
β
1–42
 peptide and the hyperphosphoryl-
ated tau protein, and initially affects brain 
areas, namely the hippocampus and other 
medial temporal lobe structures, which are 
important for memory processes (Blennow 
et al., 2006). As a consequence of the aging 
of the population, the number of patients 
with AD and other dementias, as well as the 
number of elderly people who, although 
not demented, suffer from significant 
cognitive decline, is growing worrisomely 
(Alzheimer’s Disease International, 2009).
Alzheimer’s disease is the most frequent 
cause for dementia. Indeed, the presence 
of dementia is presently required for the 
diagnosis of AD according to established 
diagnostic criteria, like the International 
Classification of Diseases (World Health 
Organization, 1992), Diagnostic and 
Statistical Manual of Mental Disorders 
(American Psychiatric Association, 1994), or 
those proposed by the National Institute of 
Neurological and Communicative Disorders 
and Stroke (McKhann et al., 1984), that is to 
say, the patient must have deficits in memory 
and other cognitive domains, representing 
a decline in relation to a previous level, and 
interfering significantly with the social and 
professional life.
However, AD begins insidiously, usually 
with memory difficulties, many years before 
the patient has a cognitive and functional 
decline compatible with the diagnosis of 
dementia. Furthermore, it is often difficult 
to appreciate the memory complaints in the 
initial phase of AD, because healthy people 
frequently report an unfavorable opinion 
about their own memory, and there is a slight 
decline in objective memory performance in 
the aging process (Mendes et al., 2008).
Several nosologic concepts were 
 proposed, in the last decades, to describe 
the patients who have cognitive deficits 
but are not demented. Of these, the one 
that became more popular was mild cog-
nitive impairment (MCI), as established 
by Petersen et al. (1999), and subsequently 
refined (Portet et al., 2006).
Certainly, clinicians interested in mem-
ory disorders have been in the last few years 
consulting younger patients and patients 
with more subtle complaints. The nosologic 
concept of MCI has been very useful to 
establish the probability of progression to 
dementia and promote an adequate follow-
up in these patients. However, the concept 
of MCI has important limitations. First of 
all, it represents a stage of cognitive decline 
between normality and dementia, rather 
than a disease (Gauthier et al., 2006). In 
second place, some patients with MCI are 
intriguingly stable and do not progress to 
dementia after many years (Petersen et al., 
2001). In third place, some patients with 
cognitive complaints who have no altera-
tions in the neuropsychological testing, and 
thus do not fulfill MCI criteria, do never-
theless progress to dementia (Nunes et al., 
2010). We must thus recognize that the con-
cept of MCI is unsatisfactory both from a 
diagnostic and prognostic point of view.
However, and very importantly, the stud-
ies performed in patients with the diagno-
sis of MCI allowed a better understanding 
of the initial phases of AD, and lead to the 
proposal of new AD criteria that can diag-
nose the disease at initial stages, before the 
patient is demented (Dubois et al., 2007; 
Albert et al., 2011). These criteria are still 
considered mainly appropriate for clinical 
research, but their use is certainly spread-
ing to specialized practice. The new criteria 
are based on the identification of patho-
logical alterations in the brain typical of 
AD, or biomarkers, namely: (1) decline in 
episodic memory, confirmed by neuropsy-
chological testing, (2) atrophy of the hip-
pocampus and other medial temporal lobe 
structures shown by magnetic resonance 
imaging using volumetric techniques, (3) 
detection of abnormal CSF biomarkers, 
namely low amyloid β1–42  concentrations, 
increased total tau concentrations, or 
increased  phosphorylated tau concentra-
tions, (4) reduced glucose metabolism in 
bilateral temporal parietal regions by posi-
tron emission tomography. In familial cases, 
the finding of a causative mutation in the 
genes responsible for autosomal dominant 
forms of the disease may establish the defi-
nite diagnosis of AD. Other genetic and 
biochemical biomarkers, as well as neu-
roimaging using radioligand compounds 
with affinity for the amyloid β
1–42
 peptide, 
are presently being developed.
We still do not know the combination 
of biomarkers most sensitive and specific 
for the early diagnosis of AD. Large mul-
ticentric studies are being conducted to 
answer this important question, but so far 
the follow-up times have been generally 
limited. In the large Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) cohort, 
the use of neuropsychological, brain imag-
ing, and CSF neurochemical biomarkers 
could only reach a predictive accuracy for 
MCI conversion to dementia of 64% (Ewers 
et al., 2010). This is not surprising, since 
the average follow-up was 2.3 years, and 
presumably many converters just had not 
the time to progress to dementia. Longer 
follow-up times will decisively be needed to 
find the best combination of biomarkers for 
an accurate early diagnosis of AD.
In conclusion, the reliable identification 
of patients with memory complaints who 
already have Alzheimer’s disease opens new 
frontiers in the management of the disease, 
since it will allow these patients to undergo 
interventions that might involve manipula-
tion of risk and protection environmental 
factors, cognitive rehabilitation procedures, 
and clinical trials with putative neuropro-
tective drugs.
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